전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved315 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleZhejiang Provincial People's Ho…Phase 1

CB CAR-NK18.2 (CB CAR-NK18.2)

Gastric Cancer; Pancreas Adenocarcinoma · Gastric Cancer

#GastricCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleXijing HospitalPhase 1

CD147-CART (CD147-CART)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleShenzhen University General Hos…Phase 2

CD276 CAR-T cells (CD276 CAR-T cells)

Advanced Pancreatic Carcinoma · Advanced Pancreatic Carcinoma

#AdvancedPancreaticCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleMiltenyi Biotec B.V. & Co. KGPhase 2

CD318-CAR-T cells (CD318-CAR-T cells)

Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleTaizhou Mabtech Pharmaceutical …Phase 1

CMAB819 (CMAB819)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase1#monoclonal-antibody#Taizhou
Trials 1Status Discontinued
AntibodyLimited DatastaleShen FengPhase 2

Cadonilimab+Gem/Cis (Cadonilimab+Gem/Cis)

Intrahepatic Cholangiocarcinoma · Intrahepatic Cholangiocarcinoma

#IntrahepaticCholangiocarcinoma#Antibody#Phase2#monoclonal-antibody#Shen
Trials 1Status Active
AntibodyLimited DatastaleJiangsu HengruiPhase 3

Camrelizumab and Cetuximab (Camrelizumab and Cetuximab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Jiangsu
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 3

Camrelizumab and Chemotherapy (Camrelizumab and Chemotherapy)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Jiangsu
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab+cetuximab+chemotherapy (Camrelizumab+cetuximab+chemotherapy)

Squamous Cell Carcinoma of Head and Neck · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
CGTLimited DatastaleShenzhen University General Hos…Preclinical

Claudin18.2 CAR-T cells (Claudin18.2 CAR-T cells)

Advanced Pancreatic Carcinoma; Advanced Gastric Carcinoma · Advanced Pancreatic Carcinoma

#AdvancedPancreaticCarcinoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

Dalpiciclib+cetuximab (Dalpiciclib+cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Dalpicilib combined with cetuximab (Dalpicilib combined with cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Zimberelizumab)

Biliary Carcinoma · Biliary Carcinoma

#BiliaryCarcinoma#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#monoclonal-antibody#Ovarian+2
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CAR30-NK (EB-CAR30-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CAR5-NK (EB-CAR5-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CARMSLN-NK (EB-CARMSLN-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

9 / 16 pages

← PreviousNext →